Abstract Circulating concentrations of low-density lipoprotein cholesterol (LDL-C) and triglyceride-rich lipoproteins are leading risk factors for atherosclerotic cardiovascular disease1. Despite several approved lipid-lowering medications, most patients fail to achieve target lipid levels under the chronic care treatment model2,3.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Zachary Glass
In Vivo CRISPR Base Editing of ANGPTL3 for Durable Lipid Lowering
|
By Taiji Mizoguchi, Jamie E DeNizio, Alexandra C. Chadwick, Anne Marie Mazzola, Maxwell Brown, Shashank Mishra, Manashree Damle, Yuri Matsumoto, Victoria Neang, Ryan Garrity, Manini Mantri, Joy Oshoname Olorife, Hui-Ting Hsu, Vian Peshdary, Estela Shabani, John Ganey, Ryan Santos, Anthony N. Federico, Sara Garcia, Pengying Hao, Yue Wu, Zachary Glass, Lisa N. Kasiewicz, Caroline Summers, Athul Sanjeev, Kui Wang, Steven D. Briscoe, Robert S. Rosenson, Christopher Cheng, Ellen Rohde, Joseph Biedenkapp, Victor Farutin, Andrew M. Bellinger, Kiran Musunuru, Sekar Kathiresan, Troy Lister, Kallanthottathil G. Rajeev, Richard Lee, Amit V. Khera
|
Nature
Verified
Abstract Circulating concentrations of low-density lipoprotein cholesterol (LDL-C) and triglyceride-rich lipoproteins are leading risk factors for atherosclerotic cardiovascular disease1. Despite several approved lipid-lowering medications, most patients fail to achieve target lipid levels under the chronic care treatment model2,3.
Protein and mRNA Delivery Enabled by Cholesteryl‐Based Biodegradable Lipidoid Nanoparticles
Research Article Qiaobing Xu Corresponding Author E-mail address: qiaobing.xu@tufts.edu Tufts University, Dept. of Biomedical Engineering, 4 Colby Street, 02155 Medford, UNITED STATES Search for more papers by this author Abstract Developing safe and efficient delivery systems for therapeutic biomacromolecules is a long‐standing challenge. Herein, we report a newly developed combinatorial library of cholesteryl‐based disulfide bond‐containing biodegradable cationic lipidoid nanoparticles.
Intracellular delivery and biodistribution study of CRISPR/Cas9 ribonucleoprotein loaded bioreducible lipidoid nanoparticles
* Corresponding authors a Department of Biomedical Engineering, Tufts University, Medford, USA E-mail: Qiaobing.Xu@tufts.edu Fax: +1 617-627-3231 Tel: +1 617-627-4322 b Beijing National Laboratory for Molecular Sciences, Key Laboratory of Analytical Chemistry for Living Biosystems, Institute of Chemistry, Chinese Academy of Sciences, Beijing, China
Intracellular delivery and biodistribution study of CRISPR/Cas9 ribonucleoprotein loaded bioreducible lipidoid nanoparticles
CRISPR/Cas9 ribonucleoprotein (RNP) complexes with transient therapeutic activity and minimum off-target effects have attracted tremendous attention in recent years for genome editing and have been successfully employed in diverse targets. One ongoing challenge is how to transport structurally and functionally intact Cas9 protein and guide RNA molecules into cells efficiently and safely.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Zachary
Contact Zachary, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack